Ernexa Therapeutics Inc.
ERNA
$4.27
-$0.03-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 71.95% | 75.29% | 68.38% | 59.18% | -82.71% |
| Total Depreciation and Amortization | -58.16% | -75.99% | -83.94% | -87.23% | -69.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | 29.68% | 255.16% |
| Total Other Non-Cash Items | -90.76% | -88.11% | -71.17% | -70.43% | 1,394.69% |
| Change in Net Operating Assets | 108.94% | 117.12% | 97.42% | -1,685.00% | -334.24% |
| Cash from Operations | 38.75% | 49.02% | 55.69% | 44.47% | 12.53% |
| Capital Expenditure | -121.05% | 85.45% | 89.97% | 94.33% | 94.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -121.05% | 85.45% | 89.86% | 94.27% | 94.79% |
| Total Debt Issued | -100.00% | -100.00% | -57.48% | -84.57% | -68.38% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 73.51% | 1,254.51% | 336.15% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | 100.00% |
| Other Financing Activities | -597.04% | -531.54% | -- | -22.73% | 52.63% |
| Cash from Financing | -20.60% | 103.59% | 15.16% | -36.55% | -31.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.14% | 199.53% | 101.56% | 72.23% | -415.89% |